ストックスクリーナーアプリを入手
5.56
4.12%
0.22
Aclaris Therapeutics Inc (ACRS) 最新ニュース
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength? - Yahoo Finance
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 2500 Growth Benchmark - marketscreener.com
Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 2000 Growth Benchmark - marketscreener.com
Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 3000E Growth Benchmark - marketscreener.com
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Price to sales forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Price to book forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Enterprise value to EBIT forward of Aclaris Therapeutics, Inc. – DUS:8AT - TradingView
Price to earnings forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Price to earnings forward of Aclaris Therapeutics, Inc. – DUS:8AT - TradingView
Enterprise value to EBITDA forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Aclaris Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACRS) - TradingView
ACRS Forecast — Price Target — Prediction for 2027 - TradingView
Aclaris Therapeutics Inc (ACRS) Institutional Confidence - TradingKey
We Think Aclaris Therapeutics (NASDAQ:ACRS) Can Afford To Drive Business Growth - Moomoo
Aclaris Therapeutics Inc (ACRS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
3 penny stocks under $5 backed by real revenue growth - MSN
Aclaris Therapeutics Inc (ACRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aclaris Therapeutics Inc (ACRS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aclaris Therapeutics Inc (ACRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aclaris Therapeutics Inc (ACRS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aclaris Therapeutics Inc (ACRS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aclaris Therapeutics Inc (ACRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aclaris Therapeutics Inc (ACRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aclaris Therapeutics Holds Steady Near Support as Biotech Sector Watches Key LevelsMomentum Factor - newsline.com
ZVRA Stock Price and Chart — NASDAQ:ZVRA - TradingView
Aclaris Therapeutics (ACRS) Gains Analyst Attention as Stifel Flags Penny Stock OpportunityEarnings Revision Report - newsline.com
Aclaris (ACRS) director Andrew Schiff reports RSU vesting and new stock option grant - Stock Titan
Aclaris Therapeutics (ACRS) director gains new RSUs and stock options - Stock Titan
Stifel Raises Aclaris Therapeutics Price Target to Four Dollars - HarianBasis.co
Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On - Insider Monkey
Aclaris Therapeutics maps busy pipeline calendar, plans phase 2 asthma trial for ATI-052 - MSN
Aclaris Stockholders Approve Directors, Pay and Auditor - TipRanks
Shareholders at Aclaris (NASDAQ: ACRS) back directors, executive pay and PwC - Stock Titan
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052 - Yahoo Finance
ACRS: All proposals passed, with no stockholder questions submitted during the meeting - TradingView
Q2 Earnings Forecast for ACRS Issued By Lifesci Capital - MarketBeat
This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesday - Benzinga
Aclaris Therapeutics Price Target Announced at $13.00/Share by LifeSci Capital - Moomoo
ACRS Initiated Coverage by LifeSci Capital -- Rating 'Outperform' - GuruFocus
Aclaris Dips Ahead of Jefferies, With Focus on 2026 Trial Data - Bez Kabli
ACRS Q1 2026 Earnings: Smaller-than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Acceleration Picks - newsline.com
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Investing News Network
Aclaris Therapeutics (ACRS) Edges Higher, Testing Key Resistance Near $4.81High Conviction Picks - The Legal Advocate
Aclaris Therapeutics (ACRS) Edges Higher, Testing Resistance After Modest UptickGrowth ETF - The Legal Advocate
Aclaris Therapeutics Holds Steady Near Mid-Range as Traders Eye Key Support and ResistanceVolume Climax - thelegaladvocate.com
Aclaris Therapeutics (ACRS) Edges Lower Amid Tight Trading RangeHigh Conviction Picks - The Legal Advocate
ACRSAclaris Therapeutics Inc Stock Price and Quote - Finviz
Aclaris Therapeutics (ACRS) Holds Near Support as Volume Suggests Cautious SentimentWedge Breakout - The Legal Advocate
Aclaris Therapeutics, Inc. Stock 12‑Month Price Target Raised to $10.2, Implies 126% Upside - TradingView
926-share sale notice for Aclaris Therapeutics (NASDAQ: ACLS) via Form 144 - Stock Titan
Aclaris (ACRS) Q1 2026 Beat: Revenue $N/A, EPS Exceeds by SignificantDividend Growth Analysis - newsline.com
Aclaris Therapeutics (ACRS) price target increased by 12.65% to 9.64 - MSN
Aclaris Therapeutics, Inc.Common Stock (NQ: ACRS - The Chronicle-Journal
Aclaris Expands Immunology Pipeline Ahead of Key Trial Data - MyChesCo
3.86%
大文字化:
|
ボリューム (24 時間):